BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

The push to keep up with COVID-19 variants could be the inflection point that turns genomic sequencing from a sophisticated technique into a widely accessible tool, with companies in the driver...
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
BioCentury | Feb 24, 2021
Deals

Feb. 23 Quick Takes: BGI raises $300M, plus a $230M C round for Clover, Day One, Waksal’s Graviton, Asalyxa

BGI Genomics Co. Ltd. (SZSE:300676) raised RMB2 billion ($309 million) through the sale of 13.8 million shares at RMB145 in a private placement. Huatai Securities Co. Ltd. purchased 8.3 million shares; also buying shares were China...
BioCentury | Feb 13, 2021
Product Development

Argenx turning cash cow into global commercialization engine

Argenx is leveraging strong investor interest in mid-cap biotechs to launch a pipeline with a global footprint, built around its autoimmune candidate efgartigimod, and is lining up two additional...
BioCentury | Feb 12, 2021
Finance

Public listing, Phase II cancer readouts in Cyteir’s sights as it banks $80M crossover round

With early efficacy signals emerging from a dose-finding study, Cyteir will use its new $80 million series C crossover round to gain Phase II data in multiple cancers for its DNA damage repair (DDR) molecule...
BioCentury | Feb 6, 2021
Regulation

The variables shaping FDA’s guidance for new SARS-CoV-2 strains

While FDA has made it clear that efficiency is a priority in adapting authorized COVID-19 products to new viral variants, questions remain about what circumstances would require a new vaccine launch, the...
BioCentury | Feb 2, 2021
Product Development

Syapse adds to real-world evidence momentum with $68M round

As the market for real-world evidence continues to grow, Syapse plans to expand its network and improve its services with a $68 million growth equity round led by Ally Bridge. Northpoint Ventures and existing investors...
BioCentury | Jan 27, 2021
Product Development

Regeneron, Lilly move toward subcutaneous mAb cocktails to treat COVID

Companies developing mAbs against COVID-19 are moving to subcutaneous injection to ameliorate deployment problems that have plagued their uptake.  FDA has authorized REGEN-COV (casirivimab/imdevimab) from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bamlanivimab from Eli Lilly and Co. (NYSE:LLY) and...
BioCentury | Jan 8, 2021
Politics, Policy & Law

FDA’s Hahn met with Biden team, plans to release pandemic response report

FDA Commissioner Stephen Hahn Friday disclosed that he has briefed President-elect Joe Biden’s transition team. Speaking to reporters at a briefing organized by the Alliance for Health Policy, Hahn also said FDA has commissioned an...
BioCentury | Jan 4, 2021
Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

CBC Group believes the maturing market for innovative products in Greater China represents an opportunity sufficient to support its launch of R-Bridge, the first discrete fund dedicated to non-dilutive investments in royalty streams and credit...
Items per page:
1 - 10 of 1048
BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

The push to keep up with COVID-19 variants could be the inflection point that turns genomic sequencing from a sophisticated technique into a widely accessible tool, with companies in the driver...
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
BioCentury | Feb 24, 2021
Deals

Feb. 23 Quick Takes: BGI raises $300M, plus a $230M C round for Clover, Day One, Waksal’s Graviton, Asalyxa

BGI Genomics Co. Ltd. (SZSE:300676) raised RMB2 billion ($309 million) through the sale of 13.8 million shares at RMB145 in a private placement. Huatai Securities Co. Ltd. purchased 8.3 million shares; also buying shares were China...
BioCentury | Feb 13, 2021
Product Development

Argenx turning cash cow into global commercialization engine

Argenx is leveraging strong investor interest in mid-cap biotechs to launch a pipeline with a global footprint, built around its autoimmune candidate efgartigimod, and is lining up two additional...
BioCentury | Feb 12, 2021
Finance

Public listing, Phase II cancer readouts in Cyteir’s sights as it banks $80M crossover round

With early efficacy signals emerging from a dose-finding study, Cyteir will use its new $80 million series C crossover round to gain Phase II data in multiple cancers for its DNA damage repair (DDR) molecule...
BioCentury | Feb 6, 2021
Regulation

The variables shaping FDA’s guidance for new SARS-CoV-2 strains

While FDA has made it clear that efficiency is a priority in adapting authorized COVID-19 products to new viral variants, questions remain about what circumstances would require a new vaccine launch, the...
BioCentury | Feb 2, 2021
Product Development

Syapse adds to real-world evidence momentum with $68M round

As the market for real-world evidence continues to grow, Syapse plans to expand its network and improve its services with a $68 million growth equity round led by Ally Bridge. Northpoint Ventures and existing investors...
BioCentury | Jan 27, 2021
Product Development

Regeneron, Lilly move toward subcutaneous mAb cocktails to treat COVID

Companies developing mAbs against COVID-19 are moving to subcutaneous injection to ameliorate deployment problems that have plagued their uptake.  FDA has authorized REGEN-COV (casirivimab/imdevimab) from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bamlanivimab from Eli Lilly and Co. (NYSE:LLY) and...
BioCentury | Jan 8, 2021
Politics, Policy & Law

FDA’s Hahn met with Biden team, plans to release pandemic response report

FDA Commissioner Stephen Hahn Friday disclosed that he has briefed President-elect Joe Biden’s transition team. Speaking to reporters at a briefing organized by the Alliance for Health Policy, Hahn also said FDA has commissioned an...
BioCentury | Jan 4, 2021
Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

CBC Group believes the maturing market for innovative products in Greater China represents an opportunity sufficient to support its launch of R-Bridge, the first discrete fund dedicated to non-dilutive investments in royalty streams and credit...
Items per page:
1 - 10 of 1048